• Home
  • Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia.

Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia.

Author List
Jung D, Long-Boyle JR, Pang WW, Gobburu JVS
Publication
Transplantation and Cellular Therapy
Publication ID (Profile URL)
https://researcherprofiles.org/profile/526293603
Publication Year
2024
PubMed ID
38972509
Publication Title
Jung D, Long-Boyle JR, Pang WW, Gobburu JVS. Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia. Transplant Cell Ther. 2024 Sep; 30(9):923.e1-923.e9.